The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
- Number of MR-Qualified MSs Reaches 840 with 376 Newly Passing MR Exam: Medipal Group
January 30, 2013
- Nesina Approved in US: Takeda
January 29, 2013
- Medipal Group Introduces Special Mini Cooler for New Orphan Drug
January 29, 2013
- Kyowa Kirin to Apply for KRN125 in 2013
January 28, 2013
- Ono, DSP Cancel Development of Limaprost for CTS
January 28, 2013
- Novartis AG: Annual Sales Down, Profits Up, Gilenya Reaches Blockbuster Status
January 28, 2013
- Market for Novel Oral Anticoagulants to Heat Up as More Companies Compete for Low-risk Patients
January 28, 2013
- Otsuka to Hire 55 Grads of 6-Year Pharmaceutical Universities as MRs in FY2013: Jiho Poll
January 25, 2013
- Novartis, Sanofi Dissolve Partnership on Equa Copromotion
January 25, 2013
- AIMIX Ranks No.1, Lotriga Soars in GP Market: Rep Track Survey
January 25, 2013
- JSMI Chief Yoshino Voices Disagreement with JMA on Epadel OTCs
January 25, 2013
- Transparency GL: Drug Makers Might Disclose Individual Payments Only Upon Request
January 24, 2013
- Takeda Establishes Trading Company in China to Serve as Base for Import of Finished Products
January 24, 2013
- Bayer, Santen Aim to Lead Market with Simpler Eylea Administration
January 24, 2013
- Merck Serono Aims for Top 10 Slot in Oncology Field
January 23, 2013
- AZ Initiates First Multinational PI Study under Agreement with NCC
January 23, 2013
- DSP Establishes Subsidiary in Singapore Eyeing Development of Business Operations for Latuda in Asia
January 23, 2013
- Kobayashi Kako, Elmed Eisai Set to Launch Allegra Generics on February 1
January 23, 2013
- Sanofi’s Dellegra Promotion to Home in on Stuffy Nose
January 22, 2013
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…